About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
PEPFAR Watch
Blog
Our Impact
Take Action
Do something now
DONATE
Access to Medicines
Access to Medicines
Congress’s Spending Bill Does Not Meet the Moment
Access to Medicines
U.S. Torpedoes Extension of WTO TRIPS Decision to Include Tests and Treatments and Hides Behind the Façade of...
Access to Medicines
Switzerland and Mexico’s Communication to the TRIPS Council is Replete with Disinformation and Their Que...
Access to Medicines
Bad Faith from Big Pharma, Rich Countries and the WTO Poison WTO TRIPS Waiver Negotiations
Access to Medicines
Time to Walk Away from the WTO Proposed Text
Access to Medicines
The Quad TRIPS Waiver Text is not a Compromise; It is an Abomination
Access to Medicines
Moderna’s Global Public Health Strategy: Parsing the Hype and Shameful Access Gaps
Access to Medicines
Merck’s Molnupiravir – Overcoming impending barriers to affordable global access
Access to Medicines
Biggest Roadblock to Biden-Convened COVID-19 Summit’s Success: Fealty to Moderna and Pfizer
Access to Medicines
Biden’s $2.7 billion investment in supply chains is a cynical boost to Big Pharma’s continued control over...
Access to Medicines
The European Union, Led by Germany’s Chancellor Merkel, Chokes Off Progress on Intellectual Property Waiver ...
Access to Medicines
Disinformation, Diversion, and Delay: The Real Text of the European Union’s Communication to the WTO TRIPS C...
Access to Medicines
The Impracticality of Relying on Compulsory Licenses to Expand Production Capacity for COVID-19 Vaccines
Access to Medicines
Debunking Pharma’s Talking Points on the TRIPS Waiver
Access to Medicines
Securing the TRIPS Waiver the World Needs: What Comes Next?
SEE MORE
